Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 September, 2017 17:16 IST
Dr Reddy's to get up to USD 32.5 mn milestone payments for DFD-06
Source: IRIS | 22 Aug, 2017, 10.33AM
Comments  |  Post Comment
 

Dr. Reddy's Laboratories, through its wholly owned subsidiary Promius Pharma, LLC, announced today that it has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis.

Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States. Promius Pharma is eligible to receive certain pre- and post-commercialization milestone payments of up to USD 32.5 million, followed by fixed royalty payments on net sales.

'We believe Encore and its management team are well positioned to realize the full potential of this asset DFD-06. We look forward to obtaining NDA approval this fall, enabling Encore's management team to quickly deliver this product to the providers and their patients." says Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products, and President, Promius Pharma.

Shares of the company gained Rs 21.85, or 1.13%, to trade at Rs 1,955.00. The total volume of shares traded was 15,230 at the BSE (10.22 a.m., Tuesday).

   

Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Infosys' arm enters into partnership with ToneTag - 22-Sep-2017 15:25
REC gets nod to incorporate 5 project specific SPVs as WOS - 22-Sep-2017 11:51
KNR Constructions' JV bags order worth Rs 8.84 bn - 22-Sep-2017 10:09
Cox & Kings owned Meininger Hotels inks pact with Swiss developer - 22-Sep-2017 10:05
Cox & Kings owned Meininger Hotels inks pact with Swiss developer - 22-Sep-2017 10:05
Zydus Cadila gets USFDA nod for Itraconazole capsules - 22-Sep-2017 10:00
Unichem Lab receives ANDA approval for anti-hypertension drug - 21-Sep-2017 09:59
NBCC receives LoI worth Rs 32 bn from Dept of Customs & Excise - 21-Sep-2017 09:57
Zydus Cadila gets USFDA's nod for Desoximetasone ointment - 21-Sep-2017 09:54
Caplin Point gets USFDA nod for Ketorolac Tromethamine injection - 20-Sep-2017 10:57
Sun Pharma's arm receives USFDA approval for new label for Odomzo - 20-Sep-2017 10:50
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer